Algert Global’s Crinetics Pharmaceuticals CRNX Stock Holding History

Algert Global’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.71M	Sell	72,532 -25,270	-26%	-$939K	0.03%	765
2026 Q1	$3.55M	Buy	+97,802	New	+$4.37M	0.05%	545
2025 Q2	–	Sell	-26,287	Closed	-$882K	–	1201
2025 Q1	$882K	Sell	26,287 -2,490	-9%	-$93K	0.02%	797
2024 Q4	$1.47M	Sell	28,777 -14,000	-33%	-$783K	0.03%	705
2024 Q3	$2.19M	Buy	42,777 +1,070	+3%	+$55.2K	0.06%	524
2024 Q2	$1.87M	Buy	41,707 +6,667	+19%	+$308K	0.06%	489
2024 Q1	$1.64M	Buy	35,040 +17,360	+98%	+$679K	0.06%	474
2023 Q4	$629K	Buy	+17,680	New	+$542K	0.03%	749
2023 Q2	–	Sell	-18,710	Closed	-$300K	–	1113
2023 Q1	$300K	Buy	18,710 +1,304	+7%	+$24.1K	0.01%	947
2022 Q4	$319K	Hold	17,406	–	–	0.02%	922
2022 Q3	$342K	Sell	17,406 -2,673	-13%	-$54.5K	0.02%	915
2022 Q2	$374K	Sell	20,079 -4,880	-20%	-$97.4K	0.03%	857
2022 Q1	$548K	Buy	+24,959	New	+$505K	0.04%	773

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Algert Global's CRNX Position: Q2 2026 in Review

Algert Global reduced its Crinetics Pharmaceuticals (CRNX) stake by 26% in Q2 2026, selling an estimated $939K and leaving 72,532 shares worth $2.71M. The position accounts for 0.03% of the portfolio, ranked #765.

Algert Global first reported a position in CRNX in Q1 2022 and has held it in 13 quarters since. The position peaked at $3.55M in Q1 2026. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Algert Global held 72,532 shares of Crinetics Pharmaceuticals worth $2.71M as of Q2 2026.
Algert Global sold 25,270 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $939K.
Crinetics Pharmaceuticals made up 0.03% of Algert Global's portfolio in Q2 2026, its #765 holding.
Algert Global first reported a position in Crinetics Pharmaceuticals in Q1 2022 and has held it in 13 quarters since.
Algert Global's Crinetics Pharmaceuticals position peaked at $3.55M in Q1 2026.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.